Cholera toxin chimera and its use as a staph vaccine

ABSTRACT

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of  Staphylococcus aureus . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from  S. aureus  and an antigenic material from a  S. aureus -specific polypeptide.

RELATED APPLICATION

This application is a continuation-in-part of U.S. patent application Ser. No. 13/328,686, filed on Dec. 16, 2011, pending. The entire teachings of the above application are incorporated herein by reference.

FEDERAL FUNDING LEGEND

This invention was supported in part with government support under USDA CREES Seed Grant #2009-01778, 2008 WWAMI ITHS Small Project Grant #3872, 2012 ITHS Small Project Grant #5617, NIH Grant #P20 RR016454 from INBRE Program of the National Center for Research Resources, and a 2012 Idaho SBOE grant #IF-13-006 The Government has certain rights in the invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 17, 2013, is named 083956-0028_SL.txt and is 53,242 bytes in size.

BACKGROUND

The present invention relates to infectious diseases and, more particularly, to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus.

Staphylococcus aureus (S. aureus) is a common cause of hospital-acquired infections and represents an important public health threat. S. aureus can cause nosocomial (hospital) and community-acquired infections including impetigo, cellulitis, food poisoning, toxic shock syndrome, invasive necrotizing pneumonia, and endocarditis. S. aureus is also the most common species of staphylococci to cause Staph infections. Currently, it is one of the top causes of infectious disease deaths in the United States.

S. aureus also causes mastitis, which is a major problem in dairy cows with considerable economic implications. For example, contagious mastitis in dairy cows is most commonly caused by S. aureus and is one of the most common diseases infecting dairy cattle in the United States. S. aureus causes a persistent, inflammatory reaction of the udder tissue that can lead to chronic infections that result in the cow being culled from the herd. Milk from cows with mastitis also typically has higher somatic cell count, which generally lowers the milk quality. It is estimated that mastitis may cost the dairy industry billions of dollars per year in economic losses.

A growing concern in the treatment of S. aureus is that the bacterium is often resistant to multiple antibiotics. Roughly half of the nosocomial isolates in the United States are methicillin-resistant S. aureus (MRSA). Methicillin-resistant S. aureus is also sometimes referred to as “multidrug-resistant” S. aureus or “oxacillin-resistant S. aureus.” MRSA bacterium is generally resistant to beta-lactam antibiotics, which include the penicillins (e.g., methicillin, dicloxacillin, nafcillin, oxacillin, etc.) and cephalosporins. Currently, a vaccine that prevents staphylococcal disease is unavailable.

A possible approach for staphylococcal vaccine development is to target virulence factors such as toxins, enzymes, polysaccharide capsules, adhesive factors, and the like. A key to the possible vaccine approach may be that the anterior nares of humans are known to be an important niche for S. aureus. It is believed that nasal carriage is a major risk factor for invasive infection.

One potential S. aureus virulence factor is the iron-regulated surface determinant A (IsdA). IsdA is an S. aureus surface adhesin protein that may be immunogenic in certain organisms. IsdA can bind to human desquamated nasal epithelial cells and is believed to play a critical role in nasal colonization.

However, a major obstacle in vaccine development of S. aureus is the lack of immunostimulatory adjuvants that can function from mucosal surfaces. While certain toxins (e.g., cholera toxin and heat-labile toxin) have the ability to induce mucosal and systemic immune responses to co-administered antigens, these bacterial proteins are generally too toxic for human use.

SUMMARY OF THE INVENTION

The present invention relates to infectious diseases and, more particularly, to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus.

In some embodiments, the present invention provides methods of generating an immune response in a mammal comprising: administering to the mammal a composition comprising: a chimeric protein comprising at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen comprising at least one of: an antigenic material from S. aureus and an antigenic material from an S. aureus-specific polypeptide.

In other embodiments, the present invention provides a method of inducing an immune response in a cow comprising: administering to the cow a chimeric protein comprising: an adjuvant selected from the group consisting of: a portion of a cholera toxin, a portion of a heat-labile toxin, a portion of a shiga toxin, and any combination thereof; and an antigen selected from the group consisting of: an antigenic material from S. aureus, an antigenic material from a S. aureus-specific polypeptide, and any combination thereof.

The features and advantages of the present invention will be readily apparent to those skilled in the art upon a reading of the description of the preferred embodiments that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

The following figures are included to illustrate certain aspects of the present invention, and should not be viewed as exclusive embodiments. The subject matter disclosed is capable of considerable modification, alteration, and equivalents in form and function, as will occur to those skilled in the art and having the benefit of this disclosure.

FIGS. 1A-1C show ribbon diagrams illustrating structures of cholera toxin, IsdA, and chimeric protein according to some embodiments.

FIG. 2 shows a diagram illustrating a plasmid that encodes a chimeric protein according to some embodiments.

FIGS. 3A-3B illustrate expression and purification of a chimeric protein according to some embodiments.

FIG. 4 shows a plot showing the results of a receptor binding affinity assay according to some embodiments.

FIGS. 5A-5D show confocal images of chimeric protein binding to Vero and DC2.4 cells stained with fluorescent dyes according to some embodiments.

FIG. 6 shows a plot showing in vivo systemic antibody response to chimeric protein according to some embodiments.

FIG. 7 shows a plot illustrating in vivo mucosal antibody response to chimeric protein according to some embodiments.

FIGS. 8A-8D show plots showing the results of flow cytometry experiments on the proliferation of T lymphocytes from mice immunized with chimeric protein according to some embodiments.

FIG. 9 shows a plot summarizing the flow cytometry results shown in FIGS. 8A-8D according to some embodiments.

FIG. 10 shows a plot showing the results of Resazurin assay of splenocytes from mice immunized with chimeric protein according to some embodiments.

FIG. 11 shows a plot showing IL-4 and IN-γ levels of antigen-stimulated splenocytes from mice immunized with chimeric protein according to some embodiments.

FIG. 12 shows a plot showing the results of IsdA-specific ELISA titrations of systemic antibody subtypes according to some embodiments.

FIGS. 13A-13B show a plot showing the effects of immune serum on S. aureus adhesion to human epithelial cells according to some embodiments.

FIG. 14A is a graph showing IsdA specific IgG serum titers in cows treated with IsdA-CTA₂/B (V) or control IsdA (C). FIG. 14B is a graph showing IsdA specific IgG milk titers in cows. FIG. 14C is a graph showing IsdA-specific IgA milk titers in cows. FIG. 14D is a graph showing IsdA-specific IgA nasal secretion titers in cows. FIG. 14E is a graph showing somatic cell counts in cows treated with IsdA-CTA₂/B or control IsdA.

FIG. 15A is an illustration of a plasmid pSKJ001 for expression of ClfA-CTA₂/B. FIG. 15B is an image of SDS-PAGE of the S. aureus ClfACTA₂/B chimera (ClfA-CTA₂ approximately 37 kD, CTB equals 11.5 kD). FT=flow through, W1=wash 1, E=elution of D-galactose column.

FIG. 16A is an illustration of a plasmid pMPEZ001 for expression of IsdB-CTA₂/B. FIG. 16B is an image of SDS-PAGE of the S. aureus IsdBCTA₂/B chimera (IsdB-CTA₂ approximately 42 kD, CTB=11.5 kD). W1=wash 1, E=elution of D-galactose column.

DETAILED DESCRIPTION

The present invention relates to infectious diseases and, more particularly, to immunogenic compositions comprising chimeric proteins and methods of use thereof in the prevention of Staphylococcus aureus.

There are a number of advantages related to the present invention. The present invention provides compositions (in some embodiments, chimeric proteins) that may be useful as vaccines against various strains of S. aureus and related bacteria in various organisms (e.g., mammals such as humans, cows, etc.).

As used herein, the term “chimeric protein” generally refers to any protein comprised of a first amino acid sequence derived from a first source, bonded, covalently or non-covalently (e.g., hydrogen bonding, van der Waals force, hydrophobic interaction, etc.), to a second amino acid sequence derived from a second source, wherein the first and second source are not the same. A first source and a second source that are not the same can include two different biological entities, or two different proteins from the same biological entity, or a biological entity and a non-biological entity. A chimeric protein can include, for example, a protein derived from at least 2 different biological sources. A biological source can include any non-synthetically produced nucleic acid or amino acid sequence (e.g., a genomic or cDNA sequence, a plasmid or viral vector, a native virion or a mutant or analog, as further described herein, of any of the above). A synthetic source can include a protein or nucleic acid sequence produced chemically and not by a biological system (e.g., solid phase synthesis of amino acid sequences). A chimeric protein can also include a protein derived from at least 2 different synthetic sources or a protein derived from at least one biological source and at least one synthetic source. For the purposes of this disclosure, a chimeric protein may or may not be a single polypeptide (i.e., a fusion protein).

In some embodiments, the immunogenic compositions may be prophylactic and may be administered before the onset of S. aureus related infections. It is believed that the immunogenic compositions of the present invention can activate humoral responses, stimulate protection, and block the promotion of oral tolerance against S. aureus. Currently, there are no known vaccines that can prevent Staphylococcal infection.

The present invention provides compositions that comprise a first amino acid sequence derived from a suitable adjuvant source and a second amino acid sequence derived from a suitable antigen source. In some embodiments, the composition may have multiple functions. For example, the first amino acid sequence may act as an adjuvant while the second amino acid sequence may act as an antigen. As used herein, the term “amino acid sequence” does not necessarily imply a single polypeptide. In other words, the amino acid sequence derived from a suitable adjuvant source may not necessarily be confined to a single polypeptide. For example, a portion of the amino acid sequence may be in one polypeptide while the remaining portion of the amino acid sequence may reside in another polypeptide.

In some embodiments, the composition may be a single polypeptide (e.g., a fusion protein). In other embodiments, the composition may be assembled from two or more polypeptides. In certain embodiments having two or more polypeptides, one or more polypeptide may be chimeric. In certain embodiments, the two or more polypeptides may fold or assemble together within a suitable expression system (e.g., E. coli) or by any other suitable method (e.g., by the use of chaperone molecules).

The adjuvants typically used to construct the chimeric proteins of the present invention may be non-toxigenic or less toxigenic than full-length or non-chimeric toxins and yet retain their potent adjuvant characteristics. In some embodiments, the adjuvant may have been modified from a toxigenic adjuvant source with a modification that renders the adjuvant non-toxigenic or less toxigenic and likely suitable for mucosal surfaces. Such modifications may include, but are not limited to, mutation of amino acid, removal of toxigenic subunits, and the like.

As used herein, an “adjuvant” generally refers to a pharmacological or an immunological agent that modifies the effect of other agents (e.g., drug or vaccine), while having few if any direct effects when given by itself. An immunological adjuvant is often included in vaccines to enhance the recipient's immune response to the antigen, while keeping the injection of foreign material to a minimum. For the purposes of this disclosure, an adjuvant may be linked covalently or non-covalently to the antigen.

While cholera toxin is an example of a potent adjuvant, it remains mostly unsuitable for use in humans. Specifically, there are safety concerns with the mucosal administration of cholera toxin and other similar toxins such as heat-labile toxin and shiga toxin. It is believed that such administration can redirect antigens to the central nervous system through GM1-dependent binding to olfactory epithelium. It has been previously difficult to separate the toxigenicity and adjuvanticity of cholera toxin, heat-labile toxin, and/or shiga toxin.

In some embodiments, the adjuvant source may be a toxin. The adjuvant may be coupled, assembled, folded, fused, or otherwise associated with an antigen to form a composition that further enhances the immunogenic effects of the antigen. Examples of suitable toxins include, but are not limited to, cholera toxin (CT), shiga toxin (ST1, ST2, etc.), heat-labile toxin (LT, LT-IIa, LT-IIb, etc.) from E. coli. In some preferred embodiments, the toxins are modified to be non-toxigenic while remaining potent immunostimulatory molecules that can bind to and target immune effector cells at mucosal site. It is believed that both shiga toxin and heat-labile toxin are structurally similar or analogous to cholera toxin.

In particular, cholera toxin is a protein secreted by the bacterium Vibrio cholerae and is generally responsible for the massive, watery diarrhea characteristic of cholera infection. Structurally, cholera toxin is an oligomeric complex made up of six protein subunits: a single copy of the A subunit (part A, enzymatic), and five copies of the B subunit (part B, receptor binding). The A subunit has two important segments: the A1 domain (CTA₁), which is toxigenic and the A2 domain (CTA₂), which forms an extended alpha helix that sits snugly in the central pore of the B subunit ring.

FIG. 1A shows a ribbon diagram of the cholera toxin crystal structure showing the CTA₁ domain (SEQ ID NO: 1) and connecting CTA₂ domain (SEQ ID NO:2), and the B subunit (SEQ ID NO: 3).

It is believed that cholera toxin immunomodulation may be involved in the activation of antigen-presenting cells, promotion of B-cell isotype switching, and upregulation of costimulatory and major histocompability complex (MHC) class II expression. Many of these responses result from the interaction of the cholera toxin B (CTB) subunit with the ganglioside GM1 receptor on effector cells, such as dendritic cells, that promote antigen uptake, presentation, and cellular activation. Thus, suitably modified non-toxigenic forms of cholera toxin by themselves may act as an antigen carrier and be highly immunostimulatory. Without being limited by theory, it is believed that heat-labile toxin and shiga toxin are structurally and functionally similar (e.g., adjuvanticity) to the cholera toxin. For example, heat-labile toxin has an A₁ domain (SEQ ID NO: 7), A₂ domain (SEQ ID NO: 8), B domain (SEQ ID NO: 9) analogous to the A₁, A₂, and B domains of cholera toxin. An IsdA-LTA₂/B chimeric protein may have a sequence shown in SEQ ID NO: 10.

An antigen is generally any substance that causes the production of antibodies against it. An antigen may be a foreign substance from the environment or it may also be formed within the environment, such as bacterial toxins or tissue cells. Examples of a suitable antigen source include, but are not limited to, iron-regulated surface determinant A (IsdA), iron-regulated surface determinant B (IsdB), clumping factor A (ClfA), clumping factor B (CIfB), fibronectin-binding protein (FnBP), penicillin binding protein 2a (PBP2A), serine-aspartate rich fibrinogen sialoprotein binding protein (SdrE), and the like.

In particular, the N-terminal near iron transporter (NEAT) domain of IsdA is capable of binding to a broad spectrum of human ligands, including transferring heme, fibrinogen, fibronectin, and corneocyte envelope proteins to mediate adherence and dissemination of S. aureus. The C-terminal domain of IsdA defends S. aureus against human skin bactericidal fatty acids and antimicrobial peptides by making the cell surface hydrophilic.

FIG. 1B shows a ribbon diagram of IsdA antigen (SEQ ID NO: 4) that is replacing the toxigenic CTA₁ domain (SEQ ID NO: 1) to construct a chimeric protein that comprises an antigen and a non-toxigenic adjuvant. FIG. 1C shows a ribbon diagram of one preferred chimeric protein, IsdA-CTA₂/B (SEQ ID NO: 5).

Some embodiments provide compositions comprising: a chimeric protein comprising at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen comprising at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.

In some embodiments, the composition is a fusion protein. In certain embodiments, the composition is a single polypeptide.

Some embodiments provide a chimeric protein comprising: an adjuvant and an antigen. The adjuvant may be selected from the group consisting of: a portion of a cholera toxin, a portion of a heat-labile toxin, a portion of a shiga toxin, and combinations thereof. The antigen may be selected from the group consisting of: an antigenic material from S. aureus (e.g., carbohydrates, peptides, etc.), an antigenic material from an S. aureus-specific polypeptide, and combinations thereof.

In some embodiments, the adjuvant is one of: CTA₂/B, LTA₂/B, or STA₂/B. In one or more embodiments, the adjuvant further includes at least one additional cholera toxin B subunit, heat-labile toxin B subunit (e.g., I or II), or shiga toxin B subunit (e.g., I or II). In one or more embodiments, the adjuvant further comprises at least one additional cholera toxin A₂ subunit, heat-labile toxin A₂ subunit (e.g., I or II), or shiga toxin A₂ subunit (e.g., I or II).

While some preferred embodiments of the domain and chimeric protein sequences have been provided, the present invention may be practiced using any number of alternative embodiments. For example, it is well known in the relevant arts that protein or polypeptide variants typically retain their function as long as they have sufficient sequence identity with their native sequences.

In some embodiments, the composition has at least about 80% sequence identity to SEQ ID NO: 5, 10, or 15. In some preferred embodiments, the composition has at least about 90% sequence identity to SEQ ID NO: 5, 10, or 15. In some preferred embodiments, the composition has at least about 95% sequence identity to SEQ ID NO: 5, 10, or 15. In certain embodiments, the antigen portion of the composition has at least about 80% sequence identity to SEQ ID NO: 4. In some preferred embodiments, the antigen portion of the composition has at least about 90% sequence identity to SEQ ID NO: 4. In some preferred embodiments, the antigen portion of the composition has at least about 95% sequence identity to SEQ ID NO: 4. In some embodiments, the composition is assembled from a first polypeptide and a second polypeptide that are non-covalently linked. In one or more of these embodiments, the first polypeptide has at least about 80% sequence identity to SEQ ID NO: 6, 11, or 16. In some preferred embodiments, the first polypeptide has at least about 90% sequence identity to SEQ ID NO: 6, 11, or 16. In some preferred embodiments, the first polypeptide has at least about 95% sequence identity to SEQ ID NO: 6, 11, or 16. In some embodiments, the second polypeptide has at least about 80% sequence identity to SEQ ID NO: 3, 9, or 14. In some preferred embodiments, the second polypeptide has at least about 90% sequence identity to SEQ ID NO: 3, 9, or 14. In some preferred embodiments, the second polypeptide has at least about 95% sequence identity to SEQ ID NO: 3, 9, or 14.

Generally, a chimeric protein will be comprised of a single A₂ subunit and a B subunit (from cholera toxin, heat-labile toxin, or shiga toxin). In some optional embodiments, the chimeric protein may further comprise at least one additional B subunit. In some optional embodiments, the B subunit may comprise five identical peptides. In some optional embodiments, the chimeric protein may further comprise at least one additional A₂ subunit. In some embodiments, the subunits may be linked by a disulfide bond. In some embodiments, the disulfide bond may be engineered. In some embodiments, the antigen has a disulfide bond with the adjuvant. In some embodiments, the antigen is associated non-covalently with the adjuvant.

In some embodiments, the antigen comprises a sequence that has at least about 80% sequence identity to iron-regulated surface determinant A (IsdA), iron-regulated surface determinant B (IsdB), clumping factor A (ClfA), clumping factor B (CIfB), fibronectin-binding protein (FnBP), fibronectin-binding protein (FnBP), penicillin binding protein 2a (PBP2A), or serine-aspartate rich fibrinogen sialoprotein binding protein (SdrE). In some preferred embodiments, the sequence identity is at least about 90%, or at least about 95%.

In some exemplary embodiments, the chimeric protein is IsdA-CTA₂/B (SEQ ID NO: 5). As used herein, “IsdA-CTA₂/B” generally refers to a chimeric protein that comprises an IsdA antigen domain, a CTA₂ subunit, and a CTB subunit. In some embodiments, each of the IsdA antigen domain (SEQ ID NO: 4), the CTA₂ domain (SEQ ID NO: 2) and the CTB domain (SEQ ID NO: 3) may be bonded covalently (e.g., peptide bonds, disulfide bonds, etc.) or non-covalently to at least one other domain. In some embodiments, the bond may be an engineered disulfide bond.

In some embodiments, the chimeric protein is IsdA-LTA₂/B (SEQ ID NO: 10). As used herein, “IsdA-LTA₂/B” generally refers to a chimeric protein that comprises an IsdA antigen domain, a LTA₂ subunit, and a LTB subunit. In some embodiments, each of the IsdA antigen domain (SEQ ID NO: 4), the LTA₂ subunit (SEQ ID NO: 8) and the CTB subunit (SEQ ID NO: 9) may be bonded covalently (e.g., peptide bonds, disulfide bonds, etc.) or non-covalently to at least one other domain. In some embodiments, the bond may be an engineered disulfide bond.

In some embodiments, the chimeric protein is IsdA-STA₂/B (SEQ ID NO: 15). As used herein, “IsdA-STA₂/B” generally refers to a chimeric protein that comprises an IsdA antigen domain, a STA₂ subunit, and a STB subunit. In some embodiments, each of the IsdA antigen domain (SEQ ID NO: 4), the STA₂ subunit (SEQ ID NO: 13) and the STB subunit (SEQ ID NO: 14) may be bonded covalently (e.g., peptide bonds, disulfide bonds, etc.) or non-covalently to at least one other domain. In some embodiments, the bond may be an engineered disulfide bond.

In some embodiments, the chimeric protein is IsdB-CTA₂/B (amino acids 24-367 of SEQ ID NO: 22). As used herein, “IsdB-CTA₂/B” generally refers to a chimeric protein that comprises an IsdB antigen domain, a CTA₂ subunit, and a CTB subunit. In some embodiments, each of the IsdB antigen domain (amino acids 42-338 of SEQ ID NO: 23), the CTA₂ subunit (SEQ ID NO: 2) and the CTB subunit (SEQ ID NO: 3) may be bonded covalently (e.g., peptide bonds, disulfide bonds, etc.) or non-covalently to at least one other domain. In some embodiments, the bond may be an engineered disulfide bond.

In some embodiments, the chimeric protein is ClfA-CTA₂/B (amino acids 24-347 of SEQ ID NO: 24). As used herein, “ClfA-CTA₂/B” generally refers to a chimeric protein that comprises a ClfA antigen domain, a CTA₂ subunit, and a CTB subunit. In some embodiments, each of the ClfA antigen domain (amino acids 287-559 of SEQ ID NO: 25), the CTA₂ subunit (SEQ ID NO: 2) and the CTB subunit (SEQ ID NO: 3) may be bonded covalently (e.g., peptide bonds, disulfide bonds, etc.) or non-covalently to at least one other domain. In some embodiments, the bond may be an engineered disulfide bond.

In some embodiments, the chimeric protein may further comprise modifications that enhance at least one of: solubility of the chimeric protein, specificity for S. aureus, specificity for GM1, expression of the chimeric protein, and immunogenicity of the chimeric protein.

Some embodiments provide methods for generating an immune response in a mammal comprising: administering to the mammal a composition (e.g., chimeric protein) according to one or more embodiments described herein.

In some embodiments, the mammal is selected from the group consisting of: a human, a cow, a dog, a cat, and a horse.

In some embodiments, the administration of the composition is by intranasal administration, oral administration, intramuscular administration, peritoneal administration, sublingual administration, transcutaneous administration, subcutaneous administration, intravaginal administration, intramammary administration or intrarectal administration. The administered dosage of the composition may generally be an amount suitable to elicit the desired immune response. In some embodiments, the administering to the mammal comprises: administering the composition to at least one cell from the mammal in vitro or in vivo.

Some embodiments provide methods for inducing an immune response in a cow comprising: administering to the cow, a chimeric protein according to one or more embodiments described herein.

To facilitate a better understanding of the present invention, the following examples of preferred embodiments are given. In no way should the following examples be read to limit, or to define, the scope of the invention.

EXAMPLE 1

To direct the IsdA-CTA₂ and CTB peptides of the chimera to the E. coli periplasm for proper assembly, pBA001 (FIG. 2) was constructed from pARLDR19, which utilizes the E. coli LTIIb N-terminal leader sequence. Induction of pBA001 and purification from the periplasm of E. coli resulted in efficient IsdA-CTA₂/B production (3 to 4 mg from 1 liter of starting culture). SDS-PAGE analysis of the purification of IsdA-CTA₂/B and immunoblotting using antibodies against CTA and CTB (FIG. 3A) confirm that IsdA-CTA₂ (˜38 kDa) was copurified with CTB (˜11 kDa) on D-galactose agarose, which is indicative of proper chimera folding. Referring to FIG. 3A, the SDS-PAGE analysis shows flowthrough (FT), washes (W1 and W2) and elution (E) of IsdA-CTA₂/B from D-galactose affinity purification and anti-CTA/B Western blot of purified IsdA-CTA₂/B (˜38 and 11 kDA).

IsdA alone was also purified using a six-histidine tag (SEQ ID NO: 26). FIG. 3B shows an SDS-polyacrylamide gel of all resulting proteins used in animal studies, as well as immunoblotting of purified IsdA with anti-His6 (“His6” disclosed as SEQ ID NO: 26) (˜37 kDa): ISdA-CTA₂/B (G1), IsdA plus CTA₂/B mixed (G2), and IsdA (G3).

The following protocol was followed in order to obtain the chimeric proteins.

MRSA252 strain was used for IsdA isolation. MRSA USA300 (pvl mutant) strain was used in adhesion assays. E. coli TE1, a ΔendA derivative of TX1, and BL21(DE3)/pLysS strains were used for protein expression. All bacterial strains were cultured using Luria-Bertani (LB) agar or broth at 37° C. with chloramphenicol (35 μg/ml), ampicillin (100 μg/ml), and/or kanamycin (50 μg/ml).

To construct pBA001 plasmid (FIG. 2) for the expression of IsdA-CTA₂/B, IsdA was PCR amplified from MRSA252 with primers that add 5′ SphI GCTACTGGCATGCGGCAACAGAAGCTACGAAC (SEQ ID NO: 17) and 3′ ClaI GTGCATGATCGATTTTGGTAATTCTTTAGC (SEQ ID NO: 18) sites (in boldface) and cloned into pARLDR19 between the LTIIb leader sequence and CTXA₂. CTB was also expressed from this vector. To make His6-IsdA IsdA (“His6” disclosed as SEQ ID NO: 26), IsdA was amplified from MRSA252 with primers that add 5′ BamHI GCTACTGGATCCGCGGCAACAGAAGCTACGAAC (SEQ ID NO: 19) or GTGCATAAGCTTTCAAGTTTTTGGTAATTCTTTAGC (SEQ ID NO: 20) and 3′ HindIII GTGCATGATCGATTTTGGTAATTCTTTAGC (SEQ ID NO: 21) sites (in boldface) and cloned into pTrcHisA (Invitrogen, Carlsbad, Calif.) or pET-40b+, yielding pBA009A and pBA015. pARLDR19 was used to express CTA₂/B for the mixed preparation. Plasmids were transformed into E. coli TE1 (pBA001, pBA009A, and pARLDR19) or BL21(DE3)/pLysS (pBA015) and sequenced.

To express IsdA-CTA₂/B and CTA₂/B, cultures with pBA001 or pARLDR19 were grown to an optical density at 600 nm (OD₆₀₀) of 0.9 and induced for 15 h with 0.2% L-arabinose. Proteins were purified from the periplasmic extract using immobilized D-galactose. For mock cultures, E. coli TE1 without plasmid was induced, and the periplasmic extract was purified. IsdA was isolated from the cytosol of cultures containing pBA009A and purified by cobalt affinity chromatography under denaturing conditions. IsdA was also purified from periplasmic extracts of cultures containing pBA015 over Talon resin under native conditions. All proteins were dialyzed against phosphate-buffered saline (PBS), reduced to <0.125 endotoxin units (EU)/ml lipopolysaccharide by passage through an endotoxin removal column, and quantified by bicinchoninic acid assay prior to the addition of 5% glycerol.

Proteins resolved by SDS-12% PAGE were stained with COOMASSIE™ or transferred to nitrocellulose membranes. Membranes were blocked overnight with 5% skim milk in PBS plus 0.05% TWEEN 20™ (PBS-T), incubated with polyclonal anti-CTA (1:2,500) and anti-CTB (1:5,000) or anti-His6 (“His6” disclosed as SEQ ID NO: 26) (1:2,500), followed by horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:5,000) and developed with IMMOBILON WESTERN HRP St. BS commercially available from Millipore, Billerica, Mass.

EXAMPLE 2

To compare the receptor binding affinity of purified IsdA-CTA₂/B chimera with native CT, ganglioside GM1 ELISA assays using anti-CTA and anti-CTB antibodies were performed.

GM1 enzyme-linked immunosorbent assays (ELISA) were performed by coating microtiter plates with 0.15 μM GM1 for 15 h at 20° C., blocking with 10% bovine serum albumin, and incubating with IsdA-CTA₂/B or CT for 1 h at 37° C. Ganglioside GM1 is found ubiquitously on mammalian cells and acts as the site of binding for both cholera toxin and heat-labile toxin. Plates were washed with PBS-T and incubated with anti-CTA (1:2,000) or anti-CTB (1:5,000) followed by HRP-conjugated anti-rabbit IgG, both for 1 h at 37° C. The reaction was developed with o-phenylenediamine dihydrochloride (A₄₅₀).

The ELISA results indicate that the B subunit of IsdA-CTA₂/B has GM1 binding affinity similar to that of CT (FIG. 4). Low anti-CTA response from IsdA-CTA₂/B was an expected result from this fusion that contains only 46 bp of full-length CTA.

Confocal microscopy was used to further confirm receptor binding and internalization of IsdA-CTA₂/B into epithelial and dendritic cells (DC) in vitro. Immune effector cells, such as dendritic cells, have a uniquely high affinity for CT and non-toxigenic CTB. FIGS. 5A-5D show anti-CT FITC-labeled IsdA-CTA₂/B bound to the surface of cells (Vero epithelial cells in FIG. 5A-5B; DC cells in FIG. 5C-5D) at 4° C. and internalization after 45 min at 37° C., indicating that, at a minimum, the CTB subunit of the chimera were efficiently imported into the cell. These images obtained using polyclonal anti-CT and anti-rabbit-FITC with DAPI suggest that IsdA-CTA₂/B was binding and transporting into Vero and DC2.4 cells. Cells were incubated with IsdA-CTA₂/B for 45 minutes at 4° C. to inhibit, or at 37° C. to promote cellular uptake.

EXAMPLE 3

The chimeric proteins were tested for their specific humoral response.

BALB/c mice were mock immunized or immunized intranasally with IsdA-CTA₂/B, IsdA plus CTA₂/B mixed, or IsdA on day 0 and boosted on day 10 (Table 1 below). FIG. 6 shows systemic antibody response to IsdA-CTA₂/B in vivo. Referring to FIG. 6, sera collected on days 0, 10, 14, and 45 were pooled by treatment group at each time point and tested for recognition of IsdA by IgG ELISA. IsdA-specific serum IgG endpoint titers from mice immunized with IsdA-CTA₂/B were significantly higher than those of mock-immunized mice on day 10, than those of all control groups on day 14, and than those of mice immunized with IsdA alone and mock-immunized mice on day 45. As used herein, “*” denotes statistical significance (P<0.05) between mice immunized with IsdA-CTA₂/B versus controls. Nasal, intestinal, and vaginal washes were collected on day 45, pooled by treatment group, and tested for recognition of IsdA by IgA ELISA.

FIG. 7 shows mucosal antibody response to IsdA-CTA₂/B in vivo. Referring to FIG. 7, the percentage of IsdA-IgA out of total IgA was significantly higher in nasal and vaginal washes from mice immunized with IsdA-CTA₂/B than from mock-immunized mice, mice immunized with IsdA plus CTA₂/B, or mice immunized with IsdA alone. In addition, intestinal IsdA-IgA was significantly higher in IsdA-CTA₂/B-immunized mice than in IsdA- and mock-immunized mice (FIG. 7). Together, these results suggest that IsdA specific systemic and mucosal humoral immunity can be stimulated after intranasal vaccination with the IsdA-CTA₂/B chimera.

TABLE 1 Immunization Strategy. Dose per Days of sampling vacci- Days of Mucosal Antigen/ nation intranasal secretions adjuvant (μg) n^(b) vaccination Sera and spleen (n) IsdA − 50 8 0, 10 0, 10, 14, 45 14 (2), 45 (6) CTA₂/B chimera IsdA + 17 + 33^(a) 8 0, 10 0, 10, 14, 45 14 (2), 45 (6) CTA₂/B IsdA 17 8 0, 10 0, 10, 14, 45 14 (2), 45 (6) Mock NA^(c) 8 0, 10 0, 10, 14, 45 14 (2), 45 (6) ^(a)Concentrations are according to equimolar to equimolar amounts of IsdA ^(b)n, number of mice ^(c)NA, not applicable

EXAMPLE 4

Cellular proliferation of IsdA-stimulated splenocytes was assessed using flow cytometry and a resazurin-based fluorescent dye assay. CFSE-based flow cytometric results suggest that day 45 splenocytes derived from mice immunized with IsdA-CTA₂/B showed significant proliferation of IsdA-specific CD3+ T lymphocytes compared with mixed and IsdA control groups (FIGS. 8A-8D and 9). Referring to FIGS. 8A-8D, CFSE-labeled splenocytes were cultured in vitro for 84 h with IsdA and stained with anti-CD3-PE-Cy5. Referring to FIG. 9, percent proliferation of IsdA-specific CD3+ T lymphocytes from individual mice on day 45 was determined by flow cytometry. Mock samples contained low numbers of CD3+ T lymphocytes.

FIG. 10 shows the result of a resazurin assay of splenocytes from days 14 and 45 cultured in vitro for 84 h with IsdA. The resazurin assays revealed that in vitro stimulation of splenocytes from IsdA-CTA₂/B-immunized mice induced significant proliferation compared with IsdA plus CTA₂/B, IsdA, and mock groups on day 45 (FIG. 10). With the low sample size (n=2 per group) on day 14, no significance was observed between groups. Error bars are based on n=2 (day 14) or n=6 (day 45). Stimulation was observed for the positive control, ConA. These results suggest that intranasal administration of IsdA-CTA₂/B can induce a cellular activation response.

EXAMPLE 5

The levels of IL-4 and IFN-γ in supernatants of splenocytes stimulated with IsdA in vitro were determined by ELISA. Referring to FIG. 11, IL-4 and IFN-γ levels in culture supernatants from splenocytes, pooled by immunization group (n=6), were stimulated in vitro for 84 h with IsdA and measured by ELISA. The splenocytes obtained from mice immunized with IsdA-CTA₂/B secreted high levels of IL-4, and these levels were significantly higher than levels of all controls (FIG. 11). Although the level of IFN-γ was slightly higher in IsdA-CTA₂/B-immune splenocytes, low levels of IFN-γ, near the detection limit for the assay, were found in all groups (FIG. 11).

FIG. 12 shows IsdA-specific IgG1 and IgG2a ELISA titrations from day 45 sera pooled by immunization group (n=6). Titrations of IgG1 and IgG2a revealed that immunization with IsdA-CTA₂/B drove isotype switching primarily to the IgG1 subclass although minute IgG2a levels were also detected. These results suggest that immunization with IsdA-CTA₂/B promotes a Th2-type immune response.

EXAMPLE 6

Pooled sera from commonly immunized mice were used to investigate the ability of immune serum to functionally block adherence of S. aureus to human epithelial cells (HeLa). FIGS. 13A-13B show the effect of immune serum on S. aureus adhesion to human epithelial cells in vitro. Referring to FIG. 13A, sera (1:100; day 45) was pooled by immunization group and incubated with MRSA252 (5×10⁷ CFU) for 1 h at 37° C. and then added to confluent HeLa cells. After washing and lysis, the number of internalized and cell-bound bacteria was enumerated. Preincubation of the S. aureus strain used for vaccination (MRSA252) with day 45 sera from IsdA-CTA₂/B-immunized mice significantly reduced bacterial adhesion to epithelial cells compared to all control groups (FIG. 13A).

FIG. 13B shows the result of similar tests performed with MRSA USA300 (5×10⁹ CFU). Referring to FIG. 13B, there was a significant reduction in bacterial adhesion to human epithelial cells after a different strain of S. aureus (MRSA USA300) was preincubated with day 45 sera from mice immunized with IsdA-CTA₂/B (FIG. 13B).

These examples suggest that the chimeric proteins of the present invention can bind and transport into epithelial and dendritic cells as consistent with the uptake of CT involving retrograde movement to the perinuclear domain of the Golgi apparatus and endoplastmic reticulum. It is believed that the ability of the chimeric proteins to bind to GM1 and trigger internalization leads to the activation of immune effector cells by the CTB subunit and promotes antigen presentation on MHC molecules.

Moreover, the ELISAs of IsdA-specific responses from the sera and nasal, intestinal, and vaginal fluids of intranasally immunized mice verifies that the chimeric proteins can induce antigen-specific systemic and mucosal immunity in mice. As expected, IgG titers were highest on day 14 after the boost and began to diminish by day 45.

These results also suggest the characteristic ability of CT to induce systemic IgG to antigens co-administered with CT at mucosal sites. The presence of IsdA-specific IgA in nasal, intestinal, and vaginal fluids after intranasal immunization with IsdA-CTA₂/B suggests that IgA blasts migrated from the nasal-associated lymphoid tissue into distal mucosal effector sites in the nasal passage and gastrointestinal and genital tracts. Thus, it is believed that CT and CT derivatives promote more of a Th2-type response, which is typically characterized by secretion of IL-4 leading to induction of antibody class switching to non-complement-activating IgG1. In vitro functional assays of antibodies revealed a significant reduction in internalized and cell-bound bacteria on human epithelial cells after preincubation of IsdA-CTA₂/B immune serum with the S. aureus isolate used for vaccination, MRSA252. Additionally, antibodies were able to prevent adhesion of MRSA USA300.

IsdA from MRSA252 and MRSA USA300 has 92% amino acid identity with the majority of differences present within the C terminus, which suggests that antibodies against IsdA are functional in vitro and may protect against multiple serotypes in vivo.

The results also suggest that the humoral and cellular responses induced by IsdA-CTA₂/B are superior to those stimulated by a mixed preparation of antigen and adjuvant (IsdA plus CTA₂/B). Thus, the structure of the IsdA-CTA₂/B chimera is optimal for the induction of antigen-specific humoral responses and potentially for presentation on MHC molecules.

EXAMPLE 7

To direct the ClfA-CTA₂ and CTB peptides of the chimera to the E. coli periplasm for proper assembly, pSKJ001 (FIG. 15A) was constructed from pARLDR19, which utilizes the E. coli LTIIb N-terminal leader sequence. SDS-PAGE analysis of the purification of ClfA-CTA₂/B confirms that ClfA-CTA₂ (˜37 kDa) was copurified with CTB (11.5 kDa) on D-galactose agarose, which is indicative of proper chimera folding. Referring to FIG. 15B, the SDS-PAGE analysis shows flowthrough (FT), wash 1 (W1) and elution (E) of ClfA-CTA₂/B from D-galactose affinity purification.

To direct the IsdB-CTA₂ and CTB peptides of the chimera to the E. coli periplasm for proper assembly, pSKJ001 (FIG. 16A) was constructed from pARLDR19, which utilizes the E. coli LTIIb N-terminal leader sequence. SDS-PAGE analysis of the purification of IsdB-CTA₂/B confirms that IsdB-CTA₂ (˜42 kDa) was copurified with CTB (11.5 kDa) on D-galactose agarose, which is indicative of proper chimera folding. Referring to FIG. 16B, the SDS-PAGE analysis shows flowthrough (FT), wash 1 (W1) and elution (E) of IsdB-CTA₂/B from D-galactose affinity purification.

EXAMPLE 8

Milk anti-IsdA IgA titer levels were measured in cows treated with a chimeric protein according to one or more embodiments of the present invention. Six (2472, 2340, 2319, 2403, 2299, 2296) clinically healthy Holstein dairy cows were vaccinated intranasally on day 0 with 300 μg of IsdA-CTA₂/B chimera (cows 2472, 2340, 2319) or an equivalent concentration of IsdA alone (cows 2403, 2299, 2296). Cows were boosted on day 14 with the same concentration. Milk was collected on days 0, 14 and 28 and analyzed by IsdA-specific IgA ELISA. Immunogenicity of the IsdA-CTA₂/B chimera was measured after intranasal delivery in dairy cows (FIGS. 14A-14E).

A. IsdA specific IgG serum titers of IsdA-CTA₂/B vaccinated cows (2472, 2340, 2319) and IsdA control vaccinated cows (2403, 2299, 2296).

Titers were calculated as the highest dilution 0.2 O.D. above background and were reported as a ratio with Day 0. Combined titers of IsdA-CTA₂/B vaccinated cows were significant over IsdA control vaccinated cows on day 49 (**Student's t-test, p-0.003)

B. IsdA specific IgG milk titers of IsdA-CTA2/B vaccinated cows (2472, 2340, 2319) and IsdA control vaccinated cows (2403, 2299, 2296).

Titers were calculated as the highest dilution 0.2 O.D. above background and are reported as a ratio with Day 0. Combined titers of IsdA-CTA₂/B vaccinated cows were significant over IsdA control vaccinated cows on days 14, 28, and 49 (*Student's t-test, p<0.05).

C. IsdA-specific IgA in milk from IsdA-CTA2/B vaccinated cows and IsdA vaccinated cows.

Levels were reported as the ratio of IsdA specific IgA over total IgA after the subtraction of Day 0 at a milk dilution of 1:8. No significant differences were detected between IsdA-CTA₂/B vaccinated cows and IsdA control vaccinated cows.

D. IsdA-specific IgA in nasal secretions from IsdA-CTA₂/B vaccinated cows and IsdA vaccinated cows.

Levels were reported as the ratio of IsdA specific IgA over total IgA after the subtraction of Day 0 at a nasal wash dilution of 1:8. No significant differences were detected between IsdA-CTA2/B vaccinated cows and IsdA control vaccinated cows.

E. Somatic cell counts throughout the study of IsdA-CTA₂/B vaccinated cows and IsdA vaccinated cows. No significant differences were detected between IsdA-CTA₂/B vaccinated cows and IsdA control vaccinated cows.

Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered, combined, or modified and all such variations are considered within the scope and spirit of the present invention. The invention illustratively disclosed herein suitably may be practiced in the absence of any element that is not specifically disclosed herein and/or any optional element disclosed herein. While compositions and methods are described in terms of “comprising,” “containing,” or “including” various components or steps, the compositions and methods can also “consist essentially of” or “consist of” the various components and steps. All numbers and ranges disclosed above may vary by some amount. Whenever a numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range is specifically disclosed. In particular, every range of values (of the form, “from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b”) disclosed herein is to be understood to set forth every number and range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. Moreover, the indefinite articles “a” or “an,” as used in the claims, are defined herein to mean one or more than one of the element that it introduces. If there is any conflict in the usages of a word or term in this specification and one or more patent or other documents that may be incorporated herein by reference, the definitions that are consistent with this specification should be adopted. 

The invention claimed is:
 1. A method of generating an immune response to Staphylococcus aureus in a mammal comprising administering to the mammal a composition comprising a chimeric protein comprising a cholera toxin A2 having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, a cholera toxin B having the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence that is at least 90% identical to SEQ ID NO: 3, and an isolated Staphylococcus aureus-specific clumping factor A (ClfA) polypeptide consisting of amino acid residues 24-300 as set forth within the amino acid sequence of SEQ ID NO:
 24. 2. The method of claim 1, wherein the chimeric protein comprises the amino acid sequence of SEQ ID NO:
 24. 3. The method of claim 1, wherein the chimeric protein is a single polypeptide.
 4. The method of claim 1, wherein the chimeric protein is a fusion protein.
 5. The method of claim 1, wherein the mammal is a cow.
 6. The method of claim 1, wherein the mammal is a human and the chimeric protein is purified.
 7. The method of claim 1, wherein the administration of the composition is selected from the group consisting of intranasal administration, subcutaneous administration, intramuscular administration, and any combination thereof. 